Tag Archive for: DeuterOncology

Weekly roundup: An A* week! Advancements, acquisitions, appointments and Series A financings!

/in ,

AMSilk Secures EUR 52M Strategic Financing to Accelerate Commercial Growth AMSilk GmbH has successfully secured EUR 52 million financing led by existing investor ATHOS (AT Newtec), along with strong participation from fellow existing investors MIG Capital and Novo Holdings. The financing will enable AMSilk to scale industrial production and meet global customer demand for its […]

Read more

DeuterOncology to Present Promising Phase I DO-2 MET Kinase Inhibitor Data at WCLC 2025

/in

DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]

Read more